AB1225 ASSOCIATION BETWEEN BONE METABOLISM MARKERS AND INCREASES IN BONE MINERAL DENSITY IN PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS TREATED WITH ROMOSOZUMAB

Background Osteoporosis is a metabolic bone disorder characterized by systemic impairment of mass and microarchitecture that results in fragility fractures [1]. Romosozumab (Rmab), humanized monoclonal anti-sclerostin antibody, increases mineral density (BMD) decreases patients with postmenopausal osteoporosis (PMO) [2]. While an increase type 1 amino-terminal propeptide (P1NP) decrease tartrate-resistant acid phosphatase 5b (TRACP-5b) are observed early after administration Rmab, the association between these changes markers (BTMs) BMDs was still unknown. Objectives The aim this research to evaluate effect Rmab on BMD BTMs PMO. Methods Between March 2019 August 2021, 34 PMO, who were naïve treatment included. correlation baseline characteristics, (%-) lumber (L-) total hip (TH-) at 12 months (-M), absolute values P1NP TRACP-5b %P1NP %TRACP-5b 1, 3, 6M calculated, respectively. Multiple regression analysis performed factors showed significant correlations L- TH-BMD, Results mean age 72.5 years old, BMI 20.6 kg/m 2 , vertebral 2.1, Th-BMD 0.762 g/cm 0.589 107.0 μg/L, 640.3 mU/dL. %L- %TH-BMD 12M 18.1% 9.1%. 3M positively correlated %L-BMD 12M, while each time point no 12M. confirmed great associated L-BMD No either or observed. Conclusion We predictive factor PMO treated Rmab. On other hand, there TH-BMD including TRACP-5b. References [1]Rachner TD, et al. Osteoporosis: now future. Lancet. 2011;9:1276-87. [2]McClung MR, women low density. N Engl J Med. 2014;370:412-20. Acknowledgements: NIL. Disclosure Interests None Declared.